<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A series of 116 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> consisted of 74 cases of RA, 10 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, 14 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 9 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> and 9 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, were studied on the quantity and morphological abnormalities of megakaryocytes in relation to over <z:hpo ids='HP_0000001'>all</z:hpo> survival and leukemic change </plain></SENT>
<SENT sid="1" pm="."><plain>The amount of megakaryocytes was graded into four groups; marked <z:mpath ids='MPATH_133'>hypoplasia</z:mpath> (O), moderate <z:mpath ids='MPATH_133'>hypoplasia</z:mpath> (L), normoplasia (N) and <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> (H), RA cases showed <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> pattern; containing 14 cases (18.9%) of group (O), 18 cases (24.3%) of group (L), 31 cases (41.9%) of group (N) and 11 cases (14.9%) of group (H) </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> cases were classified into group (N) or group (H) </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> pattern of RA did not relate to leukemic change, but over <z:hpo ids='HP_0000001'>all</z:hpo> survival tended to be shorter in group (N) cases </plain></SENT>
<SENT sid="4" pm="."><plain>A significant number of young female cases of RA were involved in group (O) </plain></SENT>
<SENT sid="5" pm="."><plain>Morphological abnormalities of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> megakaryocytes were classified into five types; I, mononuclear micromegakaryocytes, II, binuclear micromegakaryocytes, III, mononuclear small megakaryocytes, IV, multiseparated-nuclear megakaryocytes and V, megakaryocytes with bizzare nuclei </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> cases uniformly showed marked dysmegakaryopoiesis ranging from type I to V. whereas RA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> cases showed mild dysmegakaryopoiesis </plain></SENT>
<SENT sid="7" pm="."><plain>Only five cases (6.4%) of RA cases had type I micromegakaryocytes </plain></SENT>
<SENT sid="8" pm="."><plain>Eight RA cases with type I on diagnosis or obtaining it during the clinical course tended to develop <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (5 cases) or to transform to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> sooner or later </plain></SENT>
<SENT sid="9" pm="."><plain>In two cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in which hematological improvement was obtained with low dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> regimen, disappearance of type I micromegakaryocytes was noted </plain></SENT>
<SENT sid="10" pm="."><plain>A female case with 5q-anomaly surviving more than 10 years showed marked megakaryocyte <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> and almost exclusively type III and IV megakaryocytes </plain></SENT>
<SENT sid="11" pm="."><plain>These findings indicated that pattern of dysmegakaryopoiesis, especially appearance of type I, was closely related to leukemic change in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Thus quantitative and qualitative evaluations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> megakaryocytopoiesis seemed important to understand the further <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of pathophysiology in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes </plain></SENT>
</text></document>